Hadi Darvishi-Khezri

Dr. Hadi Darvishi-Khezri


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2017 in Clinics and Practice
Verified
Journal Article
Open access
HKHossein Karami
Hossein Karami
MKMehrnoush Kosaryan
Mehrnoush Kosaryan
AAArash Hadian Amree
Arash Hadian Amree
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
MMMasoomeh Mousavi
Masoomeh Mousavi
There are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this treatment regimen. The mean doses of DFP and DFX were 53.9±22.2 and 29.3±6.8 mg/kg/day, respectively. The duration of treatment was 11.5±4.6 months. Their serum ferritin levels were measured to be 2800±1900 and 3400±1600 ng/mL before and after treatment, respectively (p<0.6). Their cardiac magnetic resonance imaging (MRI) T2* values were 16.69±15.35 vs 17.38±5.74 millisecond (ms) before and after treatment, respectively (p < 0.9). Although there was no significant difference between their cardiac MRI T2* values before and after treatment statistically, the values improved after combination therapy with DFP and DFX in most of the patients. Liver MRI T2 * values were changed from 2.12±0.98 to 3.03±1.51 ms after treatment (p < 0.01); Further, their liver T2* values and liver iron concentration (LIC) were improved after treatment. Our study found that cardiac MRI T2* values, liver MRI T2* values, and LIC were improved after combination therapy with DFP and DFX in β-TM patients and that DFP and DFX combination therapy could be used to alleviate cardiac and liver iron loading.

1 December 2017 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
ESEbrahim Salehifar
Ebrahim Salehifar
MKMehrnoush Kosaryan
Mehrnoush Kosaryan
HKHossein Karami
Hossein Karami
AAAbbas Alipour
Abbas Alipour
AAAily Aliasgharian
Aily Aliasgharian

31 August 2014 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
SHSoghra Hassani
Soghra Hassani
AAAbbas Alipour
Abbas Alipour
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
AFAbolfazl Firouzian
Abolfazl Firouzian
AZAmir Emami Zeydi
Amir Emami Zeydi
PZPooneh Ebrahim Zadeh
Pooneh Ebrahim Zadeh

1 January 2016 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
AAAbbas Alipour
Abbas Alipour
AZAmir Emami Zeydi
Amir Emami Zeydi
AFAbolfazl Firouzian
Abolfazl Firouzian
GMGhahraman Mahmudi
Ghahraman Mahmudi
MOMelody Omrani-Nava
Melody Omrani-Nava
Background: Ventilator-associated pneumonia (VAP) is a type of lung infection that typically affects critically ill patients undergoing mechanical ventilation (MV) in the intensive care unit (ICU). Patients with type 2 diabetes mellitus (T2DM) are considered to be more susceptible to several types of infections including community-acquired pneumonia. However, it is not clear whether T2DM is a risk factor for the development of VAP. The purpose of this study was to determine the risk of VAP for diabetic and nondiabetic mechanically ventilated trauma patients. Materials and Methods: This study is a secondary analysis of a prospective observational study of the history of T2DM in the ICU over a period of 1 year at Imam Khomeini Hospital in Iran. A total of 186 critically ill trauma patients who required at least 48 h of MV were monitored for the occurrence of VAP by their clinical pulmonary infection score (CPIS) until ICU discharge, VAP diagnosis, or death. Results: Forty-one of the 186 patients developed VAP. The median time from hospitalization to VAP was 29.09 days (95% CI: 26.27–31.9). The overall incidence of VAP was 18.82 cases per 1,000 days of intubation (95% CI: 13.86-25.57). Risk of VAP in diabetic patients was greater than nondiabetic patients after adjustments for other potential factors [hazard ratio (HR): 10.12 [95% confidence interval (CI): 5.1–20.2); P < 0.0001)]. Conclusion: The findings show that T2DM is associated with a significant increase in the occurrence of VAP in mechanically ventilated adult trauma patients.

21 February 2016 in Advances in Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
ESEbrahim Salehifar
Ebrahim Salehifar
MKMehrnoush Kosaryan
Mehrnoush Kosaryan
AAAily Aliasgharian
Aily Aliasgharian
HJHossein Jalali
Hossein Jalali
AAArash Hadian Amree
Arash Hadian Amree
Majorβ-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis ofβ-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and iron chelation therapy. Without iron chelation therapy, iron overload will cause lots of complications in patients. Antioxidant components play an important role in the treatment of the disease. Silymarin is an antioxidant flavonoid isolated fromSilybum marianumplant. In the present study, we reviewed clinical and experimental studies investigating the use of silymarin prior to September 1, 2015, using PubMed, ISI Web of Knowledge, Science Direct, Scopus, Ovid, and Cochrane Library databases and we evaluated the potential effects of silymarin on controlling the complications induced by iron overload in patients withβ-TM. Based on the results of the present study, we can conclude that silymarin may be useful as an adjuvant for improving multiple organ dysfunctions.

13 December 2017 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
HDHadi Darvishi-Khezri
Hadi Darvishi-Khezri
ESEbrahim Salehifar
Ebrahim Salehifar
MKMehrnoush Kosaryan
Mehrnoush Kosaryan
HKHossein Karami
Hossein Karami
MMMohammadreza Mahdavi
Mohammadreza Mahdavi
AAAily Aliasgharian
Aily Aliasgharian